Gastroparesis: when the stomach empties too slowly
Full after four bites, lunch still sitting there in the evening, and the report says nothing. Gastroparesis means the stomach empties measurably too slowly, without anything blocking the exit. The path to that answer is more orderly than it feels.
All articles from the gut cluster
When 40 specialists from 19 European countries were asked to agree on shared statements about gastroparesis, only 25 of 89 statements reached a consensus. On the question of what actually happens in the stomach, no agreement was reached at all. That is not a failure of the field. That is honesty, and it explains a large part of what you experience with this topic.
You are sitting in front of half a plate. After four or five bites it is over, as if someone had pulled a door shut from the inside.
In the evening nausea joins in. Sometimes you bring up something you ate in the afternoon, barely changed, still recognisable. The scales show less than three months ago, and you did nothing to make that happen.
At the doctor there was a gastroscopy. The stomach looked fine. No ulcer, no tumour, no narrowing. You were handed a note with something about an irritable stomach on it, and the feeling that this was meant to settle the matter.
Many people know exactly this pattern. And for some of them there is a word that was not on any note: gastroparesis.
I am not writing this text so that you can hand yourself a diagnosis. I am writing it so that you can ask the right questions, and so that you can recognise when it is no longer about questions but about speed.
What you can expect here
- The definition in three parts, and why all three count
- Why the word stomach paralysis leads you astray
- Eight roads to a slow stomach, with numbers for each of them
- Weight loss injections and gastric emptying, both sides of the data
- How the scintigraphy runs, and why four hours are needed
- Breath test and capsule as alternatives
- Gastroparesis or irritable stomach: 86 percent overlap
- Why a second measured value may come out differently
- The only randomised nutrition trial in the whole field
- Medicines, pacemakers, pyloric division and their limits
- Blood sugar, stress and the vagus as the adjusting screws alongside
- The red flags where nobody waits and sees
What gastroparesis is, and what it is not
Start with the word. Gastro means stomach, paresis means paralysis. And that is exactly where the misunderstanding begins.
The stomach is not paralysed. It keeps working. It only works too slowly and too poorly coordinated to pass a meal on within the usual time. That sounds like quibbling over words, but it matters. A paralysis sounds final. The course is not.
The actual definition consists of three parts, and all three have to come together.
Three conditions, none of them optional
- Matching symptoms. Nausea, vomiting, early satiety, fullness after eating, upper abdominal pain. Everything that fits food staying in the stomach too long.
- Objectively delayed emptying. Measured, not assumed. Without a measurement there is no diagnosis, only a suspicion.
- No mechanical obstruction. No narrowing, no scar, no tumour at the stomach outlet. That has to be excluded beforehand, usually with a gastroscopy.
That is how it stands in the American ACG guideline from 2022 and in the European consensus paper from 2021 [Guideline]. There is no German guideline dedicated to gastroparesis.
The third point is the one that most often gets lost. It is at the same time the most important, because a narrowing at the stomach outlet causes exactly the same symptoms as a sluggish stomach. Anyone who reverses the order can miss an obstruction and call it gastroparesis.
The symptom picture, spelled out
Nausea and vomiting count as the cardinal symptoms in the European consensus. Added to them are the complaints that typically show up with the meal: you are full after a few bites, a pressure stays in the upper abdomen, and for a long time nothing moves.
The vomiting has one peculiarity in this picture. It often comes without the usual run up, and what comes up is sometimes hours old and still recognisable as a meal. People describe this as shaming and frightening at the same time, because it does not feel like an ordinary upset stomach.
Unintentional weight loss belongs to the picture as well. It is not a side effect to wait out, it is one of the reasons why this picture belongs in medical care.
Three pictures that cause almost the same symptoms
- Achalasia. The muscular ring at the junction between the oesophagus and the stomach does not open properly. Here too undigested food comes back up, here too there is early satiety and weight loss, often with difficulty swallowing. A gastroscopy can look unremarkable in early cases.
- Rumination syndrome. Food comes back up effortlessly without any preceding nausea, often within minutes of eating. That is a picture of its own with an approach of its own.
- Eating disorders, including self induced vomiting. With severely restricted food intake, delayed gastric emptying is a frequent measurement finding and not the cause of the symptoms.
If one of these could apply to you, it belongs on the table at the appointment. It can change the work up from the ground up. And this holds in particular for persistent vomiting in pregnancy: that has causes of its own, a work up of its own, and belongs assessed medically without delay.
These red flags belong in medical hands, not in self treatment
- Blood in the bowel movement or black, tarry stool
- Unintentional weight loss
- Fever
- Symptoms that wake you at night
- Repeated vomiting
- Difficulty swallowing
- A new, persistent change in bowel habit from around 45 to 50 years of age
- Anaemia
- Bowel cancer or an inflammatory bowel disease in the family
And specifically for this picture: when you can no longer keep fluids down, when you lose a noticeable amount of weight in a short time, when your blood sugar values run out of control.
A recommended gastroscopy, colonoscopy or laboratory work up is not replaced by any guide article and should not be postponed. This text sorts things out. It does not investigate them.
How common this really is
Precision pays off here, because very different numbers circulate online.
A team around Hye-Kyung Jung analysed eleven years of a fully recorded population in Olmsted County, Minnesota, and counted in how many people gastroparesis was established.
Of 222 possible cases, 83 met the criteria for definite gastroparesis. The following numbers come from that group. The prevalence of definite gastroparesis was 37.8 per 100,000 women and 9.6 per 100,000 men. Overall survival in this group was below that of the comparison population.
For you that means: definite gastroparesis is rare. The suspicion of it is common. These two sentences do not contradict each other, they describe two different things.
Jung HK, Choung RS, Locke GR et al. Gastroenterology. 2009;136(4):1225-1233. PMID: 19249393 · DOI: 10.1053/j.gastro.2008.12.047 [Cohort, population based]A review by Adil Bharucha puts these numbers in context and points out explicitly that most frequency studies were carried out in selected case series and not in the general population [Mechanism Review]. Anyone who applies numbers from specialist clinics to themselves is calculating with the wrong denominator.
Most people who look into the word gastroparesis do not have definite gastroparesis. That is not a devaluation of their symptoms. The symptoms are real, well described and in need of care.
It only means: the label is not the point. The point is the order. First exclude what blocks the exit. Then measure. Then talk about what can be moved.
And now you know why a doctor who wants a gastroscopy first with this picture is not brushing you off. They are following the definition.
Where it comes from: eight roads to a slow stomach
The most common question after the diagnosis is: why me?
There are several answers to that, and none of them fits everyone. Some roads are well studied, others are barely more than a plausible story. I go through them one by one and say each time how solid the number is.
1. Diabetes, the best known road
Diabetes is the best documented cause. Over years, a high blood sugar can damage the fine nerves that steer the movement of the stomach. That is the same nerve damage that makes feet go numb, only in the autonomic nervous system.
Rok Seon Choung and colleagues followed people with type 1 diabetes, type 2 diabetes and controls without diabetes in the same population over ten years.
Gastroparesis newly occurred in 5.2 percent with type 1, in 1.0 percent with type 2 and in 0.2 percent of the controls. The adjusted hazard ratio in type 1 was 33, with a very wide confidence interval from 4.0 to 274. Heartburn at the start was linked with later gastroparesis in type 1, hazard ratio 6.6.
For you that means two things. Diabetes is the strongest known risk factor. And even so the whole thing stays rare, which the authors write explicitly.
Choung RS, Locke GR, Schleck CD et al. Am J Gastroenterol. 2012;107(1):82-88. PMID: 22085818 · DOI: 10.1038/ajg.2011.310 [Cohort, historical, population based]The finding on heartburn is interesting because it is rarely mentioned. Early heartburn in type 1 diabetes could be a hint at a beginning involvement of the autonomic nervous system. A prescribed acid blocker is neither stopped nor changed in dose on your own, that belongs in medical care. What acid blockers can do and where their limits are is set out in detail in the article on heartburn and acid blockers.
2. Idiopathic, the largest group
Idiopathic means: no cause can be found. In specialist centres this is the largest group, and it has a striking profile.
Henry Parkman and the American gastroparesis consortium described 243 people with idiopathic gastroparesis from several centres.
88 percent were women, the average age was 41 years, in half of them it started suddenly, in 19 percent after an infection. Severe anxiety was found in 36 percent, severe depression in 18 percent. And 86 percent met the criteria for functional dyspepsia at the same time.
For you that means: if you were told there is no cause, that does not make you the exception, it makes you the largest group. And the anxiety and depression figures are an accompanying finding, not an attribution of cause.
Parkman HP, Yates K, Hasler WL et al. Gastroenterology. 2011;140(1):101-115. PMID: 20965184 · DOI: 10.1053/j.gastro.2010.10.015 [Cohort, registry, NIDDK consortium]3. After an infection
In one in five idiopathic cases the whole thing began after a gastrointestinal infection. You may know the same pattern from irritable bowel syndrome, where the post infectious road is particularly well described. How that runs is in the article on irritable bowel and the search for causes.
Leonid Bityutskiy, Irfan Soykan and Richard McCallum looked at people whose gastroparesis had begun after a viral infection and asked them again over the course of time.
All eleven who were followed reported a gradual improvement, had no hospital stay in the previous six months, a stable weight and were still working. The comparison group with a gradual onset showed a slowly progressing course with clearly worse quality of life.
For you that means: if it started after an infection, the outlook in the available follow up is good. But eleven people are eleven people. That is a hint, not a prognosis.
Bityutskiy LP, Soykan I, McCallum RW. Am J Gastroenterol. 1997;92(9):1501-1504. PMID: 9317072 (no DOI assigned) [Cohort, retrospective, very small]4. After operations
Precision is needed here, because a lot of half knowledge circulates. This is not about every anaesthetic and not about every abdominal operation. It is about major procedures in which the vagus nerve or the anatomy at the stomach outlet is touched.
Hui Qu and colleagues pooled 18 studies with 3,579 people after an operation on the head of the pancreas and looked for risk factors for delayed gastric emptying afterwards.
Clearly linked with it were pre-existing diabetes (odds ratio 1.49), pancreatic fistulas (2.66) and postoperative complications (4.71). An antecolic reconstruction was linked with a lower risk (0.17).
For you that means: after such procedures a delayed emptying is a known and anticipated topic. It is not a sign that something went wrong.
Qu H, Sun GR, Zhou SQ, He QS. Eur J Surg Oncol. 2013;39(3):213-223. PMID: 23294533 · DOI: 10.1016/j.ejso.2012.12.010 [Meta-analysis, k=18, n=3,579]5. Connective tissue diseases
In systemic sclerosis the connective tissue changes throughout the body, and the muscle layer of the digestive tract is not spared. A review states that the oesophagus may be involved in around 90 percent and the intestine in 40 to 70 percent of those affected [Mechanism Review].
The evidence on this is thin, though. What is available are case reports, that is the lowest level of evidence there is [Case Series, n=2]. A French paper describes two women with long standing systemic sclerosis whose symptoms improved after an endoscopic procedure at the stomach outlet. Two people do not allow a recommendation. They allow a question.
6. Parkinson
In Parkinson disease, digestion is often affected earlier than movement. That fits what is being discussed about the spread of the disease along the autonomic nervous system.
Andrew Su and a team from Stanford examined 65 people with Parkinson disease and gastrointestinal complaints with a motility capsule and a breath test.
35 percent had gastroparesis, 20 percent a delayed small bowel transit, 34 percent a bacterial overgrowth of the small intestine. The decisive part was the secondary finding: abdominal pain, bloating, nausea, vomiting and weight loss could not tell people with and without gastroparesis apart.
For you that means: from the symptom picture alone you cannot read off what a measurement would show. That is exactly why the measurement exists.
Su A, Gandhy R, Barlow C, Triadafilopoulos G. BMJ Open Gastroenterol. 2017;4(1):e000132. PMID: 28321329 · DOI: 10.1136/bmjgast-2017-000132 [Cohort, retrospective]Bacterial overgrowth of the small intestine turns up here as an accompanying finding. What it is and how it is established is in the article on SIBO in the small intestine.
7. Medicines
The medication list is the part that can most readily be moved, and therefore the most interesting one. Opioids, anticholinergics and some psychiatric medicines can slow the stomach. For the opioids the evidence is densest.
Asad Jehangir and Henry Parkman compared, in 223 people with delayed gastric emptying, those who took opioids continuously with those who did not.
The opioid group had stronger symptoms in almost every domain. The nausea lasted a median of seven instead of four hours, there were three instead of two vomiting episodes per day, and abdominal pain woke them at night more often.
For you that means: the medication list belongs on the table with this picture. And one limitation the authors name themselves: people with stronger symptoms are more likely to be given painkillers. Cause and consequence cannot be separated cleanly here.
Jehangir A, Parkman HP. World J Gastroenterol. 2017;23(40):7310-7320. PMID: 29142478 · DOI: 10.3748/wjg.v23.i40.7310 [Cohort, observational]Important with that: a painkiller that was prescribed to you is not stopped because of a blog article. What you can do is bring the list along and ask about it. Every change to painkillers, antidepressants or other long term medicines belongs in medical care.
8. What happens in the tissue
That leaves the question of what is actually different at the cell level. For that there is one of the few studies in which tissue from the full thickness of the stomach wall was taken and looked at.
Madhusudan Grover, Gianrico Farrugia and the consortium examined tissue samples from the stomach wall of people with diabetic and with idiopathic gastroparesis.
In 83 percent there were abnormalities. Most frequently: a loss of the interstitial cells of Cajal, the pacemakers of stomach movement, along with damage to the remaining cells, a conspicuous immune infiltrate with macrophages and fewer nerve fibres.
For you that means: there is something there, and it is visible. Between the diabetic and the idiopathic form there was barely any difference.
Grover M, Farrugia G, Lurken MS et al. Gastroenterology. 2011;140(5):1575-1585. PMID: 21300066 · DOI: 10.1053/j.gastro.2011.01.046 [In vitro, tissue study]The same Cajal cells turn up again in the small intestine when the question is why a bacterial overgrowth so often comes back. I do not explain it twice here, it is set out in detail in the article on motility and relapses in SIBO.
Eight roads, one picture. That is the reason why the one treatment does not exist and why anyone who promises you one knows more at this point than the European consensus does.
In practice that means something pleasant: it is worth taking the question of cause seriously instead of jumping straight to treatment. Two of the eight roads, the medication list and the blood sugar, are the ones most open to movement. That is good news.
And now you know why the first question after the diagnosis should be: which road is it in my case?
The weight loss injections: a new and frequent topic
This question has come up almost daily for two years. It often comes with fear in the tone, because in the media the word stomach paralysis stands next to the word weight loss injection.
I start with the part that is least understood: the slowing is not a fault of the medicine. It is part of how it works. GLP-1 receptor agonists slow gastric emptying among other things, and part of the feeling of fullness comes from exactly that. How these medicines work overall is in the article on how the weight loss injections work.
So the question is not whether they slow the stomach. They do, and that belongs to the documented mode of action. The question is how often this turns into a condition.
Mohit Sodhi and colleagues compared, in a large claims database, people who received GLP-1 agonists for weight loss with people on bupropion naltrexone, a different weight loss drug.
Documented gastroparesis occurred at 9.1 per 1,000 person years on semaglutide and 7.3 on liraglutide, compared with 3.1 in the comparison group. The adjusted hazard ratio was 3.67, with a confidence interval from 1.15 to 11.90.
For you that means: the signal is there. And the confidence interval runs from barely raised to twelvefold, which shows how blurred the estimate is. These are claims data, not a randomised trial.
Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. JAMA. 2023;330(18):1795-1797. PMID: 37796527 · DOI: 10.1001/jama.2023.19574 [Cohort, retrospective, research letter]A second, independent survey from the American All of Us cohort found a gastroparesis diagnosis in 5.1 percent of new users of a GLP-1 agonist. That sounds like a lot, but it is a cross section without a control group, and abdominal pain appeared there in 57.6 percent. Numbers like these describe who carries which code in a database, not how often something arises causally.
The effect wears off, and with a slow stomach it turns out small
Ryan Jalleh and an international team pooled what is known about gastric emptying under GLP-1 agonists and tirzepatide [Systematic Review]. They highlight four points explicitly.
First, these substances have a long half life. Second, activation of the GLP-1 receptor slows emptying even at the body's own concentrations. Third, with longer treatment a tachyphylaxis sets in, so the effect wears off. Fourth, in people with a pre-existing slow emptying the additional effect turns out small.
The third point matters most to me, because it changes the most in the consultation room. It shifts the picture considerably: what is measured in the first weeks is not what is left after months.
This is supported mechanistically by a paper in mice and humans at once [In vivo, mouse]. In the mouse experiment the acute delay was gone after two weeks of treatment. In humans it weakened under repeated dosing, and with type 2 diabetes and dose escalation a residual delay remained. The study comes from the manufacturer, and that belongs said alongside.
Gastroscopy and anaesthesia: the practical question
This is the question I am asked most often. Do I have to stop the injection before an examination?
The answer consists of two numbers that point in different directions.
A team around Sagar Panchal compared 360 people on a GLP-1 agonist with 298 controls at outpatient gastroscopy. The groups were not fully comparable, more people in the GLP-1 group had diabetes, 68 against 57 percent.
Solid residue in the stomach was clearly more frequent, with an odds ratio of 3.80 and a confidence interval from 1.57 to 9.21. With a concurrent colonoscopy this difference did not show. More examinations were aborted, 1.3 against 0 percent. No aspiration into the lungs occurred in this group.
For you that means: the practical problem is real and concerns whether the examination can be carried out.
Panchal S, Mahmud N, Atkins JH et al. Gastrointest Endosc. 2025;102(2):216-222. PMID: 39824444 · DOI: 10.1016/j.gie.2025.01.004 [Cohort, retrospective]Trevor Barlowe and colleagues analysed 6.8 million gastroscopies from a nationwide database and compared people with type 2 diabetes between 18 and 64 on GLP-1 agonists with those on DPP4 inhibitors.
Lung related complications were rare overall, 6 to 25 per 10,000 examinations. For aspiration the relative risk was 0.67, for aspiration pneumonia 0.95. The range, however, runs up to 1.75, and these are crude estimates. A raised risk could therefore not be demonstrated. That does not mean it is ruled out.
For you that means: the worry that was discussed most loudly could not be confirmed in this very large analysis. The analysis covered only people with type 2 diabetes in a particular age range. Not demonstrated is not the same as ruled out.
Barlowe TS, Anderson C, Sandler RS et al. Clin Gastroenterol Hepatol. 2025;23(5):739-747. PMID: 38759826 · DOI: 10.1016/j.cgh.2024.04.038 [Cohort, database analysis]The right move before a gastroscopy or anaesthesia is not to stop the medicine, it is to say so beforehand. The decision about fasting times, the approach and any pauses is made by the practice examining you. A prescribed weight loss injection is not stopped or changed in dose on your own.
Everything else about the side effects of these medicines I do not unfold here. It is in the article on the side effects of the weight loss injections.
Between a wanted slowing and a condition there is no sharp line, there is a transition. Almost everyone on these medicines has a slower stomach. In only a few does that turn into a picture that someone codes as gastroparesis.
That does not devalue the symptoms. It places them: nausea and early satiety on a weight loss injection are usually exactly the effect the medicine is given for. When they take over your life, that belongs discussed, and specifically with the practice that prescribed it.
And now you know why the answer to the weight loss injection question is neither an all clear nor an alarm, but a number with a wide confidence interval.
How it is measured, and why the scope comes first
If you are wondering why nobody simply looks into the stomach and says how fast it is: that is exactly what cannot be done. The movement cannot be seen directly. All that can be followed is how much of a meal is still inside after a set time.
That is why the road to the diagnosis looks the way it does.
Why the scope comes first and the measurement second
Gastroscopy
The absence of a mechanical obstruction is part of the definition. A narrowing at the stomach outlet, a scar after an ulcer or a tumour cause the same symptoms as a sluggish stomach. That is why the endoscopy comes first, not as a warm up but as part of the diagnosis.
Obstruction excluded Mucosa assessedGastric emptying test
Only now is anything measured. The European consensus asks for both, endoscopy and emptying test, before gastroparesis is spoken of at all [Guideline].
Scintigraphy Breath test Motility capsuleEverything around it
Go through the medication list, look at the blood sugar, check thyroid and electrolytes, record the nutritional state. With unintentional weight loss the blood values for coeliac disease belong in there too. That costs little and often changes more than any additional examination.
Medicines Blood sugar Nutritional stateOne note that prevents the greatest damage at this point: if coeliac disease testing is coming up, no gluten free eating beforehand. A gluten free diet before the examination can make the diagnosis impossible. How that work up runs is in the article on recognising coeliac disease.
The order of steps 1 and 2 comes from the ACG guideline 2022 and the UEG/ESNM consensus 2021. It matters to me to give the reasoning as well: it is that way because otherwise an obstruction can be missed.
The scintigraphy, step by step
It counts as the reference method. The principle is simpler than the name suggests.
You are given a standardised test meal. Standardised means: not just any breakfast, but a set, low fat meal based on egg white, mixed with a very small amount of a radioactive marker. A camera is then held over your abdomen, at four fixed time points: right afterwards, after one hour, after two hours and after four hours.
Two American professional societies, the one for neurogastroenterology and the one for nuclear medicine, agreed in 2008 on a uniform approach for gastric emptying scintigraphy [Guideline].
What was recommended was the low fat egg white test meal with images at 0, 1, 2 and 4 hours. The reasoning: only a uniform standard makes results reliable and comparable.
For you that means: if the examination ended after two hours, a finding may have been missed. And results from different protocols cannot simply be laid side by side.
Abell TL, Camilleri M, Donohoe K et al. J Nucl Med Technol. 2008;36(1):44-54. PMID: 18287197 · DOI: 10.2967/jnmt.107.048116 [Guideline, professional societies]From German practice information, so not from studies, come the organisational details: plan for about five hours, arrive fasting for at least six hours, and expect a radiation dose in the order of around 1.3 millisievert. That is roughly what you take in from natural radiation in Germany over half a year anyway. I mark these figures explicitly as practice information, not as study numbers.
What I deliberately do not write here are threshold values in percent. Those belong in the conversation about your report, where someone brings them together with your situation, and not in a guide article, where they invite self interpretation.
Without radiation: the breath test
Lawrence Szarka and Michael Camilleri measured gastric emptying in 38 healthy people and 129 affected people at the same time with scintigraphy and with a breath test in which 13C labelled spirulina is mixed into the test meal.
The method gets by with four breath samples. The combination of the samples at 150 and 180 minutes detected delayed emptying with 89 percent sensitivity at 80 percent specificity. And, decisively: the spread between two measurements in the same person was similarly wide for both methods, at the two hour point 13 percent with scintigraphy against 16 percent with the breath test.
For you that means: it works without radiation too. In Germany the test is only available in a limited number of places, because it is not offered everywhere.
Szarka LA, Camilleri M, Vella A et al. Clin Gastroenterol Hepatol. 2008;6(6):635-643. PMID: 18406670 · DOI: 10.1016/j.cgh.2008.01.009 [Cohort, validation study]The capsule
There is also a swallowable motility capsule that measures pressure, acidity and temperature along its way. Its advantage: it also records how long the small intestine takes. In the Parkinson study further up, exactly this method was used. In Germany availability is limited.
The imprecision does not sit in the device. It sits in the body. A stomach works at different speeds on two different days, depending on blood sugar, sleep, tension and meal. Both methods show that variation rather than calculating it away.
Many people go into this examination expecting that afterwards there will finally be clarity. What there is afterwards is a snapshot. A good, standardised, comparable one, but a snapshot.
That is no reason to skip it. Without this measurement the diagnosis would be arbitrary, and arbitrary diagnoses lead to arbitrary treatments. It is a reason not to take the value as a verdict on your condition.
And now you know why a second value may look different without anything new having happened.
Gastroparesis or irritable stomach: the distinction almost nobody makes
Now comes the part I consider the most important in this article, because clinically it concerns the most frequent mix up.
Next to gastroparesis stands a second picture: functional dyspepsia, colloquially the irritable stomach. According to the Rome IV criteria it is about fullness after eating, early satiety, upper abdominal pain and upper abdominal burning that remain unexplained after a routine work up [Guideline]. What the irritable stomach is exactly I do not explain again here. That is set out in detail in the article on functional dyspepsia.
Here it is only about one question: how do you tell the two apart?
The honest answer: from the symptoms, practically not at all.
Pankaj Jay Pasricha and the American consortium followed 944 people at specialist centres over 48 weeks, 720 of them initially classified as gastroparesis, 224 as functional dyspepsia, and measured again at the end.
42 percent of the gastroparesis group were reclassified as functional dyspepsia on the basis of the second measurement, 37 percent of the dyspepsia group the other way round as gastroparesis. The switch in either direction did not come with a difference in the course of symptoms. In the full thickness biopsies both groups showed the same loss of Cajal cells and of certain macrophages.
For you that means: if your report reads differently the second time, that is not an error and not a progression of the disease. It is the known property of this measured value.
Pasricha PJ, Grover M, Yates KP et al. Gastroenterology. 2021;160(6):2006-2017. PMID: 33548234 · DOI: 10.1053/j.gastro.2021.01.230 [Cohort, prospective, multicentre]One limitation absolutely belongs with it: these were tertiary care centres. People end up there when a lot has already remained unclear. In a family practice the distribution looks different. Even so the finding stays remarkable, because the same people were measured twice.
The measured value is not worthless, it is a weak signal
It would be one sided to leave it at Pasricha. Priya Vijayvargiya and a team from the Mayo Clinic pooled 92 studies and examined whether delayed emptying is connected with upper abdominal symptoms [Meta-analysis, k=92].
25 of these 92 papers supplied usable numbers for the meta-analysis. Across all studies it looked weak. But when only the methodologically optimal measurements were analysed, connections showed with nausea (odds ratio 1.6), vomiting (2.0) and early satiety and fullness (1.8). For abdominal pain the estimate was 1.5, but its range starts exactly at 1.0. That connection is therefore the weakest of the four.
The point that follows: part of the dispute in this field is a dispute about measurement quality. Where measuring was done cleanly, a signal shows up. It is only weaker than the word gold standard suggests.
Vijayvargiya P, Jameie-Oskooei S, Camilleri M et al. Gut. 2019;68(5):804-813. PMID: 29860241 · DOI: 10.1136/gutjnl-2018-316405 [Meta-analysis, k=92]Why the guidelines separate them anyway
At this point it would be easy to place yourself above the specialist field. I consider that wrong, for two reasons.
First: without an objective criterion the diagnosis would be arbitrary. Everyone with nausea and fullness would get the label, and then it would no longer mean anything. The measurement can protect against overdiagnosis.
Second: the categories have different consequences. With a confirmed, marked emptying disorder the nutritional state belongs under closer watch, and some procedures only come into consideration then at all.
Since 2025 Germany has had its own S1 guideline on functional dyspepsia, issued by the German Society for Neurogastroenterology and Motility [Guideline]. On gastroparesis there is nothing of its own here. That gap is itself a finding. It explains why the information people receive turns out so differently.
If your scintigraphy came back normal and you are still full after four bites: that is not imagination and not a reason to end the search.
In the best available study on this, 37 percent of the people with an initially normal finding moved into the other category within just under a year, without their symptoms changing accordingly. The measured value describes one day. It does not describe you.
And now you know why the question gastroparesis or irritable stomach is less of an either or question than the two words suggest.
What is actually studied when it comes to eating
On this topic the same order meets you almost everywhere: low fat, low fibre, small portions, liquid components.
These recommendations are not wrong. They are only justified differently in one place than almost everywhere it is written. And for this whole field there is exactly one randomised trial.
Eva Olausson and a Swedish team around Magnus Simrén divided 56 people with insulin treated diabetes and gastroparesis into two groups: one on usual food, one on a diet whose components were deliberately broken down into very small pieces.
In the intervention group nausea and vomiting improved (P = 0.01), as did fullness after eating (P = 0.02), bloating (P = 0.006) and belching and heartburn (P = 0.02). Abdominal pain did not improve. Weight, HbA1c and nutrient intake did not differ at the end.
For you that means: small particle size is the only element in the whole field that has been tested in a randomised way. And abdominal pain did not respond to it.
Olausson EA, Störsrud S, Grundin H et al. Am J Gastroenterol. 2014;109(3):375-385. PMID: 24419482 · DOI: 10.1038/ajg.2013.453 [RCT, n=56]And now the secondary finding the authors noted themselves and which is rarely mentioned alongside: the intervention group took in more fat than the comparison group.
That changes the order. In this trial the effect did not come through less fat. It may have come through the texture of the meal. It remains a secondary finding of a single study, and that is exactly how it should be read.
What the stomach does with a meal before it passes it on
- The stomach breaks solid food down until the pieces are small enough to pass through the stomach outlet. That is work, and this work needs force and coordination.
- If both are limited, this breaking down takes longer. What arrives small already needs less breaking down.
- Liquid leaves the stomach by a different route than solid and usually faster. That is why liquid or pureed components are mechanistically obvious.
- Fat can slow emptying through hormonal feedback. That is the reason for the classic fat recommendation, and it is physiologically correct.
- Only: in the single randomised trial the effect of particle size was stronger than the disadvantage of the higher fat share.
Points 1 to 4 are well grounded mechanistically. Point 5 is a single study result in 56 people with diabetes. Both belong side by side rather than one against the other.
The European consensus confirmed nutritional therapy as one of only three accepted treatment options [Guideline]. The detailed rules behind it, meaning smaller portions, less insoluble fibre, softer texture, come mostly from clinical tradition and not from studies. That is no reason to discard them. It is a reason to name them for what they are.
What I deliberately do not write here: no meal plan, no portion sizes, no number of meals per day. What fits you depends on your weight, your blood sugar, your symptoms and your daily life. That belongs in a dietary consultation, not in an article.
Fibre: a different rule applies here
In the rest of the gut cluster I keep encouraging you to eat more plant variety. With a very slow stomach the opposite applies temporarily, at least for the coarse, insoluble fibres. They need more breaking down work and can in extreme cases clump together into a solid mass.
That this exception exists does not devalue the general rule. Why the famous number 30 is more nuanced than it sounds is in the article on the fibre myths.
The bigger risk is called undersupply
Now comes the section I consider the most important one in practice and the one that often gets too little space in guide texts.
The same American consortium recorded in detail what 305 people with diabetic or idiopathic gastroparesis took in over the day.
On average it was 1,168 kilocalories, so 58 percent of the estimated requirement. 194 people, that is 64 percent, were below 60 percent of their requirement. Calculated undersupply for vitamin A, B6, C and K as well as for iron, potassium and zinc was more frequent in the idiopathic than in the diabetic form. Only a third took a multivitamin preparation. And only 32 percent had ever received any dietary counselling at all.
For you that means: the danger with this picture rarely comes from the slow stomach itself. It comes from too little arriving, and from nobody asking about it.
Parkman HP, Yates KP, Hasler WL et al. Gastroenterology. 2011;141(2):486-498. PMID: 21684286 · DOI: 10.1053/j.gastro.2011.04.045 [Cohort, registry, multicentre]Iron and zinc are the two I meet most often, because both depend on a working uptake in the upper digestive tract. What iron deficiency has to do with the gut is in the article on iron deficiency and absorption problems. Why the other micronutrients hang together as cofactors in energy metabolism is in the article on micronutrients and energy.
Two notes belong right beside this, because both substances are named above. Vitamin K can affect how coumarin anticoagulants work. And potassium is not something to supplement on your own with impaired kidney function. What is actually missing in you is shown by a measurement, and what follows from it belongs discussed.
Stomach acid first
Before I think about enzymes or supplements with a sluggish upper abdomen, I ask a different question: is there enough acid up there at all? Without sufficient acid, protein digestion may start less well, and the stomach might get its usual signals at reduced strength. That is a physiological consideration, not an established causal chain, and studies on this connection in delayed gastric emptying are scarce.
That is my fixed order in practice. It is not a guideline recommendation, and I present it here explicitly as a clinical way of working, not as a proven therapy. How this question is examined at all and where the limits are is in the article on low stomach acid and betaine HCl.
Digestive enzymes come after this question with me, not before it. When they can make sense and when they only cost money is in the article on digestive enzymes.
Most people with this picture first try to eat less, because then less happens afterwards. That is understandable and brings short term relief.
The number from the registry turns the perspective around: in almost two thirds, too little is the problem, not too much. So the question is not what you can leave out, but how enough reaches you without making you feel ill. That is a different question, and it needs different help.
And now you know why dietary counselling with this picture is not a nicety but the part with the best evidence.
Medicines and procedures: what they can do and where they end
Before I discuss anything individually here, the frame belongs in front of it. It comes from the European consensus process, and it is unusually open.
Of 89 statements, 25 reached a consensus. Only three building blocks were confirmed as appropriate therapies: nutritional therapy, dopamine 2 antagonists and 5-HT4 receptor agonists. On proton pump inhibitors, further antiemetics, further prokinetics, neuromodulators, complementary, psychological and more invasive procedures, no consensus was reached.
UEG and ESNM, European Delphi consensus 2021, 40 specialists from 19 countries [Guideline]I do not read that as weakness. I read it as honesty. Anyone who says of two thirds of their own questions that there is no agreement makes the field more honest, not worse. And it explains why the information people receive varies so much.
All the agents named in this section are prescription only. They belong in medical hands, and existing medication is never changed or stopped on your own. I give no regimens here. Where an amount appears, it is the dose from the study in question and not a recommendation to you.
A point of its own that often goes missing on this topic
Persistent vomiting in pregnancy has causes of its own and a work up of its own. It belongs assessed medically without delay and not filed away as a gastric emptying disorder.
For the medicines named in this section, separate rules apply in pregnancy and breastfeeding, in part restrictions, in part contraindications. The same holds for herbal remedies and for supplements. None of this is taken in that situation without medical advice.
Prokinetics
Metoclopramide is the best known representative. It is prescription only. What matters is the limit the European Medicines Agency drew after its 2013 review, in force since 2014 [Regulatory decision]: use is restricted to short periods of at most five days, and the long term treatment of chronic pictures such as gastroparesis is no longer among the approved indications. Anything beyond that would be use outside the marketing authorisation, that is off label, with an extended duty of explanation and justification on the prescribing practice.
The reason for that limit is a movement disorder, tardive dyskinesia. It is rare, but it can persist after the medicine is stopped. Other possible unwanted effects come on top, among them tiredness, diarrhoea, inner restlessness and motor restlessness. With bleeding, an obstruction or a perforation in the digestive tract, with epilepsy, with Parkinson's disease and after a previous tardive dyskinesia, the substance must not be given [Product information].
How high the tardive dyskinesia risk is has been reassessed twice. A review from 2010 arrived at clearly below 1 percent instead of the 1 to 10 percent previously assumed [Mechanism Review]. A reassessment from 2019 arrived at an order of magnitude of about 0.1 percent per 1,000 patient years and named the risk groups: older women, people with diabetes, people with liver or kidney failure and people on concurrent antipsychotic medication [Mechanism Review]. The same paper names the regulatory restriction on long term use in the same breath.
Both papers estimate the risk lower than was previously assumed. They do not lift the restriction. What follows from that in the individual case is weighed up by the prescribing practice, not by a blog article.
The 5-HT4 agonist
Florencia Carbone and a team around Jan Tack in Leuven gave 34 people with gastroparesis four weeks of prucalopride and four weeks of placebo each, in random order and double blinded.
The total score of the symptom index was 1.65 on prucalopride against 2.28 on placebo (P less than 0.0001), the half emptying time 98 against 143 minutes (P = 0.005). There were three dropouts because of nausea and headache and one serious event, a small bowel volvulus.
For you that means: here there is a clean positive signal. And it comes from a single centre, from 34 people, over four weeks.
Carbone F, Van den Houte K, Clevers E et al. Am J Gastroenterol. 2019;114(8):1265-1274. PMID: 31295161 · DOI: 10.14309/ajg.0000000000000304 [RCT, n=34, double blind crossover]Prucalopride is prescription only, and in gastroparesis it would be off label
In Germany prucalopride is approved solely for the treatment of chronic constipation. The paper quoted names that in its own first sentence. In gastroparesis its use would be use outside the marketing authorisation, that is off label. That has consequences: the prescribing practice carries an extended duty of explanation and justification, and the costs are not covered as a matter of course.
The risk side belongs beside it. In the trial there were three dropouts on prucalopride because of nausea and headache and one serious event, a small bowel volvulus. The 2 milligrams are the study dose and not a recommendation. Whether this comes into question for you is not decided by this article but by the practice that knows you.
What did not respond
Henry Parkman and the consortium tested nortriptyline, a tricyclic antidepressant, against placebo in idiopathic gastroparesis in the NORIG trial.
The primary endpoint was reached by 23 percent on nortriptyline and 21 percent on placebo (P = 0.86). Dropouts were more frequent on nortriptyline, 29 against 9 percent. The authors write that their findings do not support its use.
For you that means: this class of substances is still named as an option for this picture. This study then belongs in the weighing up.
Parkman HP, Van Natta ML, Abell TL et al. JAMA. 2013;310(24):2640-2649. PMID: 24368464 · DOI: 10.1001/jama.2013.282833 [RCT, n=130, multicentre double blind]The gastric pacemaker
Philippe Ducrotte and a French network implanted a stimulation device in 172 people and switched it on or off in random order for four months each, without those affected knowing which state currently applied.
With the device switched on, vomiting was clearly less frequent (P less than 0.001). Gastric emptying was not accelerated by it, and quality of life did not improve. The effect also showed up in people with normal gastric emptying.
For you that means: this is the most elegant demonstration that symptom and measured value are two different things. Something can reduce vomiting without making the stomach faster.
Ducrotte P, Coffin B, Bonaz B et al. Gastroenterology. 2020;158(3):506-514. PMID: 31647902 · DOI: 10.1053/j.gastro.2019.10.018 [RCT, n=172, multicentre crossover]The endoscopic pyloric division
Jan Martinek and a European team carried out the first sham controlled study on the endoscopic division of the pylorus. Part of the group received the procedure, the other a convincingly staged sham treatment.
After six months 71 percent of the procedure group counted as a success against 22 percent of the sham group (P = 0.005). Recruitment was ended early after an interim analysis. The authors write explicitly that the results are not conclusive for the idiopathic and the postoperative form.
For you that means: in this trial the procedure showed an effect beyond the sham treatment. And 22 percent got clearly better without any procedure at all.
Martinek J, Hustak R, Mares J et al. Gut. 2022;71(11):2170-2178. PMID: 35470243 · DOI: 10.1136/gutjnl-2022-326904 [RCT, n=41, sham controlled pilot]What belongs beside that number
It is an endoscopic procedure with the risks that go with it, among them bleeding and injury to the stomach wall. How long the effect holds beyond the six months is not established.
On top of that: the trial was stopped early after an interim analysis and did not reach the planned sample of 86. For the idiopathic and the postoperative form the authors explicitly call their results not conclusive. A success figure from 41 people is a number from a pilot trial and not an expectation for you.
21 percent improved in the NORIG trial on a tablet without an active substance. 22 percent improved after a sham treatment in the endoscopy room. Two completely independent studies, practically the same number. That is the yardstick against which every personal report has to be measured, yours and mine.
Herbal options, honestly placed
Ginger is the remedy people ask about most often. There is a decent small study on it, and its result cuts both ways.
A Taiwanese team around Keng-Liang Wu gave 24 healthy volunteers, double blinded, either 1,200 milligrams of ginger capsules or a dummy preparation, followed by a low nutrient soup.
The half emptying time was 13.1 minutes on ginger against 26.7 minutes on placebo (P less than 0.01), with more frequent contractions in the lower part of the stomach. For not a single gastrointestinal symptom was there a difference.
For you that means: ginger can speed up gastric emptying in healthy people. Whether that changes anything about symptoms in people with gastroparesis has never been studied.
Wu KL, Rayner CK, Chuah SK et al. Eur J Gastroenterol Hepatol. 2008;20(5):436-440. PMID: 18403946 · DOI: 10.1097/MEG.0b013e3282f4b224 [RCT, n=24, double blind crossover]A second small randomised study in 32 ventilated people in an intensive care unit found better tolerance of tube feeding and more ventilator free days on ginger extract [RCT, n=32]. That is a completely different situation from yours, and I mention it only so that you know what statements about ginger rest on.
A food, not a medicine, and still not arbitrary
In larger amounts ginger can affect blood clotting. Anyone taking anticoagulants or platelet inhibitors, anyone facing an operation, anyone who is pregnant or breastfeeding, anyone with gallstones, discusses this with a doctor first.
The 1,200 milligrams are the amount from the study and not a recommendation to you.
On acupuncture it is widely said to be the complementary measure with the best results. I did not find a solid primary source for that in preparing this article, and in the European consensus process no agreement was reached on complementary procedures. That does not mean there is nothing to it. It means the evidence does not carry such a sentence.
Bezoars, briefly and without home remedies
When food residues stay in the stomach for a very long time, they can clump together into a solid mass, a bezoar. That is rare and it is one of the reasons why gastroparesis belongs in medical care. Home remedy ideas circulate for bezoars. I write none here. A bezoar belongs assessed endoscopically and treated medically.
The usual story goes: there are too few treatments for this picture. I read the evidence differently. There are several treatments, and for most of them we know fairly precisely how much they contribute. For some that is more than nothing, for some it is no more than a sham treatment.
That is uncomfortable and relieving at the same time. If something did not help you, that is not down to you. And if something did help you, you may take that seriously, even when the study base is thin. You only need to know that roughly a fifth get better without an active substance too.
And now you know why I always ask about the comparison group with this topic.
Blood sugar, vagus and stress: the three adjusting screws alongside
There are three things that can slow the stomach without showing up in the diagnosis. They are the reason why the same person can eat normally on some days and gives up after three bites on others.
The blood sugar
A Swedish and Australian team around Eva Schvarcz held the blood sugar of healthy people and of people with diabetes artificially at 4 and then at 8 mmol/l and measured gastric emptying during it.
At 8 mmol/l, 55.2 percent of the solid meal was still in the stomach after 100 minutes, at 4 mmol/l only 36.7 percent (P = 0.004). And that applied to the healthy people as well. The half emptying time for the liquid part rose from 32.2 to 57.0 minutes.
For you that means: a raised blood sugar can slow the stomach. That is not a special diabetes rule, that is ordinary physiology, and in this study it showed up in healthy people too.
Schvarcz E, Palmér M, Aman J et al. Gastroenterology. 1997;113(1):60-66. PMID: 9207262 · DOI: 10.1016/s0016-5085(97)70080-5 [Cohort, experimental crossover]Now comes the counter evidence, and it belongs directly alongside. An Austrian working group changed the therapy in ten people with type 2 diabetes. The fasting value fell from 11.7 to 7.9 mmol/l. Gastric emptying stayed unchanged. So short term peaks can slow things down, but the brake does not release again straight away when the values get better over a week. Ten people are few, and that belongs said alongside.
In diabetes this turns into a loop that I often explain: a slow stomach can make it unpredictable when the sugar from a meal arrives. Unpredictable curves make control harder. High values can slow the stomach further. Where this loop can best be broken depends on the individual case. What blood sugar spikes are at all and what influences them is in the article on blood sugar spikes and nutrition.
Stress
A Korean team around Hyun Seok Lee had eight healthy volunteers eat a test meal once in quiet and once under continuous noise.
The half emptying time under noise was 130.8 minutes against 105.0 minutes in quiet (P = 0.005). Fullness and discomfort after eating were clearly stronger. The ability of the upper stomach to adjust to the meal, by contrast, did not differ.
For you that means: acute stress can slow emptying measurably. In eight people. That is a hint at a mechanism, not a solid order of magnitude.
Lee HS, An YS, Kang J et al. J Gastroenterol Hepatol. 2013;28(11):1699-1704. PMID: 23800263 · DOI: 10.1111/jgh.12309 [Cohort, randomised crossover]What matters to me here is the attitude. Stress is an amplifier here, not a diagnosis and certainly not an accusation. In the American registry, 36 percent had severe anxiety and 18 percent severe depression. That is an accompanying finding. Anyone who does not know for months whether a meal will stay down becomes tense from that, and not the other way round.
Please get support
In an acute crisis, or with thoughts of taking your own life: in Germany, Telefonseelsorge on 0800 111 0 111 or 0800 111 0 222, around the clock and free of charge. In acute danger, call 112. Outside Germany, use your local emergency number and crisis line.
This is not a footnote. Persistent nausea, weight loss and months of uncertainty wear people down, and there is help for that which need not have anything to do with the stomach.
The vagus
The vagus nerve steers a large part of stomach movement. So the obvious idea would be to stimulate it. There is a controlled study on this, and it has one important catch.
Yi Zhu and a Chinese team stimulated the vagus branch at the ear and compared that with a sham stimulation. The adjustment of the stomach to the meal improved (P = 0.008), as did the share of regular gastric waves and, after two weeks, the symptoms and the anxiety and depression scores. The catch: the people studied had functional dyspepsia, not gastroparesis. That limitation is not a formality, it decides how far the result carries.
How the gut brain axis hangs together overall and what can actually be influenced at the vagus is in the article on the gut brain axis and vagus stimulation. Here it stays with these two sentences.
The three adjusting screws do not appear in the diagnosis, because they are not a cause in the narrow sense. But they help decide how a day goes.
That is the part where something can move without waiting for a new treatment. Not as a substitute for the work up. As the thing that runs alongside it.
And now you know why the question about good and bad days in the consultation is not politeness but diagnostics.
When it becomes urgent, and what a sensible next step looks like
Up to here it was about sorting things out. Now it is about speed.
There are situations in which no guide article and no search for causes is called for any more, but a medical assessment, and promptly.
With these red flags nobody waits and sees
- You can no longer keep fluids down. Dehydration develops faster than it feels.
- Persistent or repeated vomiting. Especially when it goes on for days.
- Rapid unintentional weight loss. Without you having done anything to bring it about.
- Blood in the bowel movement or black tarry stool. Always, without exception.
- Difficulty swallowing. When food sticks in the throat or behind the breastbone.
- Fever or symptoms that wake you at night.
- Blood sugar values running out of control in diabetes. Upwards or downwards.
- Anaemia, a new persistent change in bowel habit from around 45 to 50 years of age, bowel cancer or an inflammatory bowel disease in the family.
And for the acute case: with persistent vomiting and circulatory weakness, with severe abdominal pain, with vomiting blood or with impaired consciousness, the emergency department or the emergency number is the right route. In Germany that is 112. Not an appointment next week.
One more word about a differential diagnosis that belongs with recurrent vomiting and belongs named factually: cannabinoid hyperemesis syndrome. In the Rome IV criteria it is a category of its own and it concerns people who use cannabis regularly. Said without moralising: if that applies to you, it belongs on the table at the medical appointment, because it changes how things are read.
The sequence I consider sensible
Six steps, in this sequence
- 1. Exclude an obstruction
- Gastroscopy before anything else happens. It is part of the diagnosis, not its prelude.
- 2. Measure
- Scintigraphy over four hours, or a breath test, depending on availability. In the knowledge that the value is allowed to fluctuate.
- 3. Go through the medication list
- Opioids, anticholinergics, GLP-1 agonists and a few more can slow the stomach. This is the point with the best ratio of effort to yield. Changes only through a doctor, never on your own.
- 4. Look at the blood sugar
- In diabetes anyway, in everyone else at least once. A high value can slow things down in healthy people too.
- 5. Dietary counselling
- The building block with the best evidence and at the same time the one only a third of those affected have ever received. With an eye on the texture of the meal and on the question of whether enough arrives.
- 6. Everything else
- Medicines and procedures, with realistic expectations and in the knowledge that roughly a fifth get better under a sham treatment too.
Steps 1 and 2 come from the guidelines. The order of steps 3 to 6 is my clinical way of working and not a guideline recommendation. I mark it explicitly as such.
What can be said about the course
The word everyone is looking for here I deliberately avoid, because the data do not carry it. What can be said is the following.
When the symptoms began after an infection, the follow up looked good: all eleven people followed reported a gradual improvement, stayed weight stable and able to work. Eleven people are a small number, and the study looked backwards. With other causes the course depends on the cause according to the European consensus, and that is exactly how cautiously the consensus is worded there.
The most frequent mistake with this picture is not the wrong treatment. It is the convenient label. Anyone who assigns themselves gastroparesis and therefore skips a recommended examination is trading uncertainty for a word.
A word is not a work up. And a work up that has already been recommended is not postponed because an article on the internet offered an explanation.
And now you know why I started this text with the order and not with the treatment.
Frequently asked questions about gastroparesis
What exactly is gastroparesis?
Three things have to come together: symptoms that fit food held back in the stomach, objective evidence of delayed gastric emptying and the absence of a mechanical obstruction at the stomach outlet. That is the wording of the ACG guideline from 2022. If one of the three is missing, the diagnosis has not been fully made.
Is the stomach really paralysed in gastroparesis?
No. The word stomach paralysis is common, but it describes the thing wrongly. The stomach keeps working, only too slowly and too poorly coordinated. That is more than quibbling over words, because a paralysis sounds final, and the course is not.
How do I tell gastroparesis apart from an irritable stomach?
From the symptoms, not at all. In the American registry, 86 percent of people with idiopathic gastroparesis met the criteria for functional dyspepsia at the same time. The difference sits in the measured value alone, and that value shifts over time. More on the irritable stomach is in the separate article on it.
Why does a gastroscopy have to come before the measurement?
Because the absence of a mechanical obstruction is part of the definition. A narrowing at the stomach outlet, a scar or a tumour can cause exactly the same symptoms. The European consensus therefore asks for both, an endoscopy and a gastric emptying test.
How does a gastric emptying scintigraphy work?
You eat a standardised, low fat test meal based on egg white that carries a weak radioactive label. Images are then taken at 0, 1, 2 and 4 hours. The four hour point is the decisive one, and stopping after two hours misses findings. From German practice information rather than from studies: it takes up half a day, and you arrive fasting.
Is there a measurement without radiation?
Yes. The breath test with 13C labelled spirulina was about as reproducible as scintigraphy in the validation study. The method gets by with four breath samples. The combination of the samples at 150 and 180 minutes detected delayed emptying with 89 percent sensitivity at 80 percent specificity. In Germany it is only available in a limited number of places.
Can the weight loss injection trigger gastroparesis?
Slower gastric emptying is part of how these medicines work. In an analysis of claims data the rate of documented gastroparesis was 9.1 per 1,000 person years on semaglutide compared with 3.1 on a different weight loss drug, with an adjusted hazard ratio of 3.67 and a very wide confidence interval from 1.15 to 11.90. At the same time the effect wears off under continued treatment.
Do I have to stop the weight loss injection before a gastroscopy or anaesthesia?
That decision belongs to the practice treating you, not to you. Solid residue in the stomach was more frequent in one cohort, with an odds ratio of 3.80. A raised risk of aspiration could not be demonstrated in a very large database analysis, the relative risk was 0.67. That analysis, however, covered only people with type 2 diabetes between 18 and 64, the estimates were crude, and the range runs up to 1.75. Not demonstrated therefore does not mean ruled out. Say before the appointment that you take the medicine, and change nothing on your own.
What should I eat?
A principle instead of a plan: small particle size. It is the only element in this field that has been tested in a randomised trial. It included 56 people with insulin treated diabetes, and there nausea, vomiting and fullness improved. Abdominal pain did not improve. The remarkable part: the intervention group took in more fat. So the effect may have come through the texture of the meal rather than through the amount of fat. What fits you specifically belongs in a dietary consultation.
Can ginger or herbal remedies contribute anything?
In 24 healthy volunteers ginger halved the half emptying time from 26.7 to 13.1 minutes. Nothing changed in the gastrointestinal symptoms, and it has never been tested in people with gastroparesis. On acupuncture, the European consensus process explicitly reached no agreement.
Does gastroparesis go away again?
The word most people are looking for here does not fit what the data show. In a small retrospective follow up of eleven people whose symptoms had started after an infection, the condition improved in all eleven. Eleven people are eleven people. That is a hint, not a prognosis, and nothing follows from that number for your own course. With other causes the course depends on the cause, according to the European consensus.
Why is my second measurement different from the first?
Because the variation sits in the body and not in the device. The spread between two measurements in the same person was similarly wide for scintigraphy and for the breath test. And in a prospective study over 48 weeks a considerable share of people changed diagnostic category without their symptoms changing accordingly.
What does my blood sugar have to do with it?
More than most people assume. At a blood sugar of 8 instead of 4 mmol/l, more than half of the solid meal was still in the stomach after 100 minutes instead of a good third, and that was true in healthy people too. Conversely, one week of better control did not speed up emptying in a small study. Short term peaks can slow things down, but the brake does not release again straight away.
Why is there no German guideline of its own on gastroparesis?
Since 2025 there has been a German S1 guideline on functional dyspepsia, but nothing of its own on gastroparesis. What counts are the American ACG guideline from 2022 and the European UEG/ESNM consensus from 2021. This gap explains part of the uncertainty in German speaking countries.
When do I need to see a doctor quickly?
When you can no longer keep fluids down, when you vomit repeatedly, when you lose weight unintentionally in a short time, with blood in the bowel movement or black tarry stool, with fever, with difficulty swallowing, with symptoms that wake you at night, with anaemia and with blood sugar values running out of control. These red flags belong in medical hands and are not for self treatment.
Where the stomach docks onto the rest of the body
A slow stomach does not stand on its own. It hangs on the nutrient supply, on the nervous system, on the blood sugar and on what happens further down the digestive tract.
Iron deficiency and the gut
Why iron runs short first when absorption is impaired
Micronutrients and energy
The cofactors without which calories do not become usable energy
Gut brain axis
What the vagus steers and what can be influenced there
Histamine intolerance
A second road to nausea and pressure after eating
Bile and digestion
What happens after the stomach and why fat plays a role in it
Sleep and microbiome
Why bad nights come through into digestion
Scientific sources
- Camilleri M, Kuo B, Nguyen L et al. ACG Clinical Guideline: Gastroparesis. Am J Gastroenterol. 2022;117(8):1197-1220. PMID: 35926490 · DOI: 10.14309/ajg.0000000000001874 [Guideline, GRADE]
- Schol J, Wauters L, Dickman R et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European Gastroenterol J. 2021;9(3):287-306. PMID: 33939892 · DOI: 10.1002/ueg2.12060 [Guideline, Delphi]
- Schol J, Wauters L, Dickman R et al. Parallel publication of the same consensus text. Neurogastroenterol Motil. 2021;33(8):e14237. PMID: 34399024 · DOI: 10.1111/nmo.14237 [Guideline]
- Storr M, Andresen V, Frieling T et al. Leitlinie zur funktionellen Dyspepsie, einer Störung der Darm-Hirn-Interaktion (DGBI): S1-Leitlinie der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). Z Gastroenterol. 2025;63(4):403-422. PMID: 40199346 · DOI: 10.1055/a-2518-1430 [Guideline, German S1 guideline]
- Abell TL, Camilleri M, Donohoe K et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J Nucl Med Technol. 2008;36(1):44-54. PMID: 18287197 · DOI: 10.2967/jnmt.107.048116 [Guideline]
- Abell TL, Camilleri M, Donohoe K et al. Parallel publication of the same consensus recommendation. Am J Gastroenterol. 2008;103(3):753-763. PMID: 18028513 · DOI: 10.1111/j.1572-0241.2007.01636.x [Guideline]
- Stanghellini V, Chan FKL, Hasler WL et al. Gastroduodenal Disorders. Gastroenterology. 2016;150(6):1380-1392. PMID: 27147122 · DOI: 10.1053/j.gastro.2016.02.011 [Guideline, Rome IV classification]
- Pasricha PJ, Grover M, Yates KP et al. Functional Dyspepsia and Gastroparesis in Tertiary Care are Interchangeable Syndromes With Common Clinical and Pathologic Features. Gastroenterology. 2021;160(6):2006-2017. PMID: 33548234 · DOI: 10.1053/j.gastro.2021.01.230 [Cohort, n=944, prospective]
- Vijayvargiya P, Jameie-Oskooei S, Camilleri M et al. Association between delayed gastric emptying and upper gastrointestinal symptoms: a systematic review and meta-analysis. Gut. 2019;68(5):804-813. PMID: 29860241 · DOI: 10.1136/gutjnl-2018-316405 [Meta-analysis, k=92]
- Parkman HP, Yates K, Hasler WL et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptom onset, delay in gastric emptying, and gastroparesis severity. Gastroenterology. 2011;140(1):101-115. PMID: 20965184 · DOI: 10.1053/j.gastro.2010.10.015 [Cohort, n=243, registry]
- Grover M, Farrugia G, Lurken MS et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology. 2011;140(5):1575-1585. PMID: 21300066 · DOI: 10.1053/j.gastro.2011.01.046 [In vitro, full thickness biopsies]
- Jung HK, Choung RS, Locke GR et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136(4):1225-1233. PMID: 19249393 · DOI: 10.1053/j.gastro.2008.12.047 [Cohort, population based]
- Choung RS, Locke GR, Schleck CD et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol. 2012;107(1):82-88. PMID: 22085818 · DOI: 10.1038/ajg.2011.310 [Cohort, historical, population based]
- Bharucha AE. Epidemiology and natural history of gastroparesis. Gastroenterol Clin North Am. 2015;44(1):9-19. PMID: 25667019 · DOI: 10.1016/j.gtc.2014.11.002 [Mechanism Review, narrative]
- Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis, clinical characteristics and long-term outcomes. Am J Gastroenterol. 1997;92(9):1501-1504. PMID: 9317072 (no DOI assigned) [Cohort, n=11 followed, retrospective]
- Qu H, Sun GR, Zhou SQ, He QS. Clinical risk factors of delayed gastric emptying in patients after pancreaticoduodenectomy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013;39(3):213-223. PMID: 23294533 · DOI: 10.1016/j.ejso.2012.12.010 [Meta-analysis, k=18, n=3,579]
- Su A, Gandhy R, Barlow C, Triadafilopoulos G. Utility of the wireless motility capsule and lactulose breath testing in the evaluation of patients with Parkinson's disease who present with functional gastrointestinal symptoms. BMJ Open Gastroenterol. 2017;4(1):e000132. PMID: 28321329 · DOI: 10.1136/bmjgast-2017-000132 [Cohort, n=65, retrospective]
- Gonzalez JM, Granel B, Barthet M, Vitton V. G-POEM may be an optional treatment for refractory gastroparesis in systemic sclerosis. Scand J Gastroenterol. 2020;55(7):777-779. PMID: 32634328 · DOI: 10.1080/00365521.2020.1761997 [Case Series, n=2]
- Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795-1797. PMID: 37796527 · DOI: 10.1001/jama.2023.19574 [Cohort, retrospective, claims data]
- Jalleh RJ, Plummer MP, Marathe CS et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1-15. PMID: 39418085 · DOI: 10.1210/clinem/dgae719 [Systematic Review]
- Aldhaleei WA, Abegaz TM, Bhagavathula AS. Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals (Basel). 2024;17(2):199. PMID: 38399414 · DOI: 10.3390/ph17020199 [Cohort, n=10,328, cross section]
- Panchal S, Mahmud N, Atkins JH et al. Endoscopy and anesthesia outcomes associated with glucagon-like peptide-1 receptor agonist use in patients undergoing outpatient upper endoscopy. Gastrointest Endosc. 2025;102(2):216-222. PMID: 39824444 · DOI: 10.1016/j.gie.2025.01.004 [Cohort, n=598, retrospective]
- Barlowe TS, Anderson C, Sandler RS et al. Glucagon-Like Peptide-1 Receptor Agonists Do Not Increase Aspiration During Upper Endoscopy in Patients With Diabetes. Clin Gastroenterol Hepatol. 2025;23(5):739-747. PMID: 38759826 · DOI: 10.1016/j.cgh.2024.04.038 [Cohort, n=6,806,046, database]
- Urva S, Coskun T, Loghin C et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020;22(10):1886-1891. PMID: 32519795 · DOI: 10.1111/dom.14110 [In vivo, mouse, plus phase 1 part, manufacturer study]
- Jehangir A, Parkman HP. Chronic opioids in gastroparesis: Relationship with gastrointestinal symptoms, healthcare utilization and employment. World J Gastroenterol. 2017;23(40):7310-7320. PMID: 29142478 · DOI: 10.3748/wjg.v23.i40.7310 [Cohort, n=223, observational]
- Schvarcz E, Palmér M, Aman J et al. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology. 1997;113(1):60-66. PMID: 9207262 · DOI: 10.1016/s0016-5085(97)70080-5 [Cohort, experimental crossover]
- Holzäpfel A, Festa A, Stacher-Janotta G et al. Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration. Diabetologia. 1999;42(12):1410-1412. PMID: 10651258 · DOI: 10.1007/s001250051311 [Cohort, n=10, intervention]
- Szarka LA, Camilleri M, Vella A et al. A stable isotope breath test with a standard meal for abnormal gastric emptying of solids in the clinic and in research. Clin Gastroenterol Hepatol. 2008;6(6):635-643. PMID: 18406670 · DOI: 10.1016/j.cgh.2008.01.009 [Cohort, n=167, validation study]
- Olausson EA, Störsrud S, Grundin H et al. A small particle size diet reduces upper gastrointestinal symptoms in patients with diabetic gastroparesis: a randomized controlled trial. Am J Gastroenterol. 2014;109(3):375-385. PMID: 24419482 · DOI: 10.1038/ajg.2013.453 [RCT, n=56, 20 weeks]
- Parkman HP, Yates KP, Hasler WL et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology. 2011;141(2):486-498. PMID: 21684286 · DOI: 10.1053/j.gastro.2011.04.045 [Cohort, n=305, registry]
- Carbone F, Van den Houte K, Clevers E et al. Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study. Am J Gastroenterol. 2019;114(8):1265-1274. PMID: 31295161 · DOI: 10.14309/ajg.0000000000000304 [RCT, n=34, double blind crossover]
- Parkman HP, Van Natta ML, Abell TL et al. Effect of nortriptyline on symptoms of idiopathic gastroparesis: the NORIG randomized clinical trial. JAMA. 2013;310(24):2640-2649. PMID: 24368464 · DOI: 10.1001/jama.2013.282833 [RCT, n=130, multicentre]
- Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31(1):11-19. PMID: 19886950 · DOI: 10.1111/j.1365-2036.2009.04189.x [Mechanism Review]
- Al-Saffar A, Lennernäs H, Hellström PM. Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. Neurogastroenterol Motil. 2019;31(11):e13617. PMID: 31050085 · DOI: 10.1111/nmo.13617 [Mechanism Review, reassessment]
- Ducrotte P, Coffin B, Bonaz B et al. Gastric Electrical Stimulation Reduces Refractory Vomiting in a Randomized Crossover Trial. Gastroenterology. 2020;158(3):506-514. PMID: 31647902 · DOI: 10.1053/j.gastro.2019.10.018 [RCT, n=172, double blind crossover]
- Martinek J, Hustak R, Mares J et al. Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis: a pilot, randomised, sham-controlled trial. Gut. 2022;71(11):2170-2178. PMID: 35470243 · DOI: 10.1136/gutjnl-2022-326904 [RCT, n=41, sham controlled]
- Lee HS, An YS, Kang J et al. Effect of acute auditory stress on gastric motor responses to a meal in healthy volunteers. J Gastroenterol Hepatol. 2013;28(11):1699-1704. PMID: 23800263 · DOI: 10.1111/jgh.12309 [Cohort, n=8, randomised crossover]
- Zhu Y, Xu F, Lu D et al. Transcutaneous auricular vagal nerve stimulation improves functional dyspepsia by enhancing vagal efferent activity. Am J Physiol Gastrointest Liver Physiol. 2021;320(5):G700-G711. PMID: 33624527 · DOI: 10.1152/ajpgi.00426.2020 [Cohort, sham stimulation controlled]
- Wu KL, Rayner CK, Chuah SK et al. Effects of ginger on gastric emptying and motility in healthy humans. Eur J Gastroenterol Hepatol. 2008;20(5):436-440. PMID: 18403946 · DOI: 10.1097/MEG.0b013e3282f4b224 [RCT, n=24, double blind crossover]
- Shariatpanahi ZV, Taleban FA, Mokhtari M, Shahbazi S. Ginger extract reduces delayed gastric emptying and nosocomial pneumonia in adult respiratory distress syndrome patients hospitalized in an intensive care unit. J Crit Care. 2010;25(4):647-650. PMID: 20149584 · DOI: 10.1016/j.jcrc.2009.12.008 [RCT, n=32, double blind, intensive care]
- Nassar M, Ghernautan V, Nso N et al. Gastrointestinal involvement in systemic sclerosis: An updated review. Medicine (Baltimore). 2022;101(45):e31780. PMID: 36397401 · DOI: 10.1097/MD.0000000000031780 [Mechanism Review, narrative]
- There is no German guideline on gastroparesis. Everything stated here as a guideline statement comes from the American ACG guideline 2022, the European UEG/ESNM consensus 2021 or the consensus recommendation on scintigraphy from 2008. From the German S1 guideline on functional dyspepsia only what stands in the abstract is quoted here, because the full text was not freely accessible.
- The specialist field does not agree on two thirds of its own questions. Of 89 statements in the European consensus, 25 reached agreement of at least 80 percent. On the question of what produces the symptoms in the tissue, no consensus was reached. That stands at the beginning of this article and applies to everything that follows.
- The numbers on the distinction come from tertiary care centres. The 42 and 37 percent category switches and the 86 percent overlap were collected in people for whom a lot had already remained unclear. In a family practice the distribution looks different.
- The nutrition recommendation rests on a single randomised trial with 56 people, all of them with diabetes. The finding on the higher fat share is a secondary finding of that study and has never been tested in its own right. The remaining detailed rules come from clinical tradition.
- The GLP-1 numbers come from claims and registry data, not from randomised trials. The confidence interval of the most quoted estimate runs from 1.15 to 11.90. The tachyphylaxis observation rests among other things on a manufacturer study with a mouse component.
- Several pieces of evidence rest on very small numbers. Eleven people for the outlook after an infection, eight for the stress measurement, ten for the blood sugar counter evidence, two for systemic sclerosis. These numbers justify questions, not recommendations.
- The vagus stimulation study was carried out in functional dyspepsia, not in gastroparesis. Transferring it is an obvious step and still not proven.
- On acupuncture I found no solid primary source, although it is widely named as a complementary measure with successes. In the European consensus process no agreement was explicitly reached on it.
- The widely quoted frequency figure of 10 to 30 per 100,000 could not be confirmed in the primary literature and contradicts the only population based survey. That is why its numbers stand here and not the familiar ones.
- Ginger has never been tested in people with gastroparesis. The studies quoted concern healthy people and ventilated people in an intensive care unit. Both are different situations.
- The approval status belongs with the substances named. Metoclopramide is restricted by the regulator to at most five days and is no longer approved for the long term treatment of gastroparesis. Prucalopride is approved for the treatment of chronic constipation, and in gastroparesis its use would be off label. Both stand at the relevant place in the text and belong in every weighing up.
- Three pictures that can cause the same symptoms belong in the work up. Achalasia, rumination syndrome and eating disorders including self induced vomiting. A gastroscopy does not rule out early achalasia or an eating disorder. That is why they stand in the text and not only here.
- What deliberately does not stand here. No meal plan, no portion sizes, no number of meals, no dosing instruction. The study doses named are literature figures and not a recommendation. And at no point does it follow from this text that a prescribed medication should be changed, reduced or stopped on your own, not even before an examination. Every adjustment belongs in medical care. A recommended gastroscopy, colonoscopy or laboratory work up is not replaced by this article and should not be postponed. What I describe from my consultation is marked as an observation and is not a study result.